German biotech SME specializing in drug-induced liver injury diagnostics and pharmaceutical safety biomarker qualification.
METAHEPS GmbH is a German biotech SME based in Planegg (near Munich) that specializes in drug safety testing, with a core focus on drug-induced liver injury (DILI) — one of the leading causes of drug failure and withdrawal in pharmaceutical development. They develop and apply biomarker-based diagnostic tools to detect hepatotoxicity earlier and more accurately, using patient blood samples rather than invasive procedures. Their work sits at the intersection of preclinical safety science and clinical diagnostics, directly supporting pharmaceutical companies in identifying liver toxicity risks during drug development. In EU projects, they contribute specific expertise in liver safety biomarker qualification and translational safety assessment pipelines.
DILITEST (coordinator, 2015–2016) targeted blood-based diagnosis and exclusion of DILI; TransBioLine (participant, 2019–2025) extended this into a broader safety biomarker qualification pipeline.
TransBioLine (2019–2025) is explicitly focused on developing and implementing novel safety biomarkers for pharmaceutical safety assessment across multiple organ systems.
Participation in TransBioLine, a large RIA consortium bridging preclinical models and clinical patient data, positions METAHEPS in the translational gap between lab-based and patient-derived safety evidence.
METAHEPS entered H2020 in 2015 as coordinator of DILITEST, a tightly scoped SME feasibility study aimed at a specific clinical problem: diagnosing drug-induced liver injury from patient blood. No broad keyword portfolio — just one precise diagnostic challenge. By 2019, their next EU engagement had shifted to TransBioLine, a six-year RIA consortium explicitly framed around building a validated safety biomarker pipeline, suggesting a move from single-test development toward participation in industry-wide qualification frameworks. The trajectory points from solo-driven clinical diagnostics toward integrated consortium-scale translational research, with safety biomarker qualification now the defining thread.
METAHEPS is broadening from niche DILI diagnostics toward pharmaceutical safety biomarker qualification at the consortium level, aligning with growing EMA and FDA interest in qualifying new safety biomarkers as regulatory-grade tools.
METAHEPS has operated at both ends of the collaboration spectrum: coordinating a small, solo-driven SME feasibility study (DILITEST) and joining a large multinational RIA consortium (TransBioLine). Their 29 unique partners across 11 countries from just two projects reflects the scale of TransBioLine rather than a broad independent network, suggesting they are sought out as a specialist contributor rather than a consortium builder. As a small SME, they most likely bring focused hepatotoxicity or DILI domain expertise to larger projects, rather than taking on broad coordination responsibilities.
With 29 unique partners across 11 countries from just two projects, METAHEPS is embedded in a wide European pharmaceutical safety research network, largely through TransBioLine's large consortium footprint. Their geographic spread signals good cross-border exposure despite their small size.
METAHEPS occupies a narrow but high-value niche: translating liver safety research into biomarker-based diagnostics that pharmaceutical developers can actually use in drug development workflows. Located in Planegg near Munich — one of Europe's densest biotech clusters — they combine SME focus with deep scientific specialization in DILI, a field where FDA and EMA qualification of new safety biomarkers is an active regulatory and commercial priority. For a consortium that needs a DILI-specific expert or liver safety biomarker validation capability, METAHEPS is a precise fit that larger generalist partners cannot replicate.
